Here are the latest additions to UBS’ ’Pan-European Small & Mid-Cap’ list

UBS added eight and removed eight stocks from its European small- and mid-cap “Top 20” list; it reported the list was up 18.6% in 2026 versus 9.1% for the MSCI Europe Small Cap index. UBS sees notable upside to several targets, including 71.8% for Huber+Suhner and 60% for Basic-Fit, while forecasting Huber+Suhner sales of 2.2 billion Swiss francs by 2030 and Inficon 2026 sales of $804 million versus $785 million consensus. UBS cautioned that smaller-cap stocks have lower trading volumes and can be more volatile; Siltronic’s near-term earnings are expected to remain weak.

Analysis

This is an analyst-screening event, not evidence of a broad earnings inflection. The list’s historical outperformance is not a reliable forward signal by itself: changing constituents, selection effects, and thin trading can amplify both performance and drawdowns. Treat UBS’s targets as hypotheses to test, not price anchors.

The cleaner structural setup is Huber+Suhner (HUBN): data-centre and defence demand could support a multi-year growth re-rating, but the large forecast sales ramp makes execution and order conversion the key variables. A premium versus its own history may emerge before reported revenue does, leaving the stock vulnerable to project delays or capex digestion. Scout24 (G24) is a more balanced contrarian case: AI could improve search and lead quality, but could also weaken listing-platform pricing power if users or brokers bypass the platform. Watch monetization metrics, not AI headlines.

Salzgitter (SZG) has potential policy-driven price support, but higher landed import costs do not guarantee domestic producers capture the spread; demand, energy costs, and implementation or substitution responses matter. INFICON (IFCN) is a near-term estimate-revision setup, while De’Longhi (DLG)’s cash acquisition adds capital-allocation and integration risk. Small-cap liquidity raises gap risk around results. The thesis weakens if HUBN order intake fails to convert, G24 monetization deteriorates, or EU steel measures fail to constrain effective imports.

Key Decisions for Investors

• Prefer a staged long in HUBN over buying the entire UBS basket: initiate only on stable price action and confirmation in order intake/backlog; add after evidence of revenue conversion. Cut or reassess if orders weaken or management delays growth milestones. The upside is a multi-year growth re-rating; the principal risk is that expectations outrun execution.
• Keep G24 on a contrarian watchlist rather than chasing the target gap. Consider a starter long only if listing volumes and revenue per listing remain resilient through upcoming results; reduce exposure if monetization or customer retention weakens. AI disruption is not yet a demonstrated earnings outcome.
• For SZG, treat EU safeguards as a catalyst, not a standalone long thesis. Wait for evidence that domestic realized prices and margins improve; reassess if import volumes remain high or steel demand/energy costs offset tariff support.
• IFCN is a short-horizon event watch: compare reported guidance and order trends with the raised expectations embedded in analyst forecasts. Avoid adding ahead of results without confirmation; a failure to lift guidance could unwind the estimate-revision thesis.
• Do not trade the full UBS list as a single factor basket. Its mixed business drivers and lower liquidity make constituent selection and position sizing more important than the headline list performance.